JAGX

Jaguar Health, Inc. (JAGX) | Rumor.io

Jaguar Health

JAGX

Attention (50-day avg)0.01%

Attention rank (50-day avg)#375

Bullish sentiment (50-day avg)72%

Price to earnings ratio0.01

Market capitalization3.1M

Earnings per share1.5K

Dividend yield (TTM)—

Revenue (annual)11.5M

Net income (annual)-54M

Social

What share of all stock conversation is about JAGX?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0.02% -0.02	0.08% +0.04	0.02% +0.02	0% 0

Sep 29

Jaguar Health, Inc. has had a preliminary open-label study in adult short bowel syndrome patients with intestinal failure accepted for presentation at the annual American College of Gastroenterology meeting.
The study results involve the use of crofelemer, a product Jaguar Health, Inc. is developing, and the meeting is scheduled for October 9-14, 2026.
Some analysts predict a massive short squeeze to $50 for Jaguar Health, Inc.'s stock, with one post stating that the stock is "going to be big" and another predicting a price increase of $0.50+.

Generated by AI

Sentiment

Of the messages about JAGX that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	81.94% +17.77	72.05% -0.12	71.71% -11.15	65.56% +4.82
Bearish	18.06% -17.77	27.95% +0.12	28.29% +11.15	34.44% -4.82

Bullish· Sep 29

$JAGX is surging 500-600% and has a massive short squeeze coming soon, potentially reaching $50.
The company has released fantastic news, making it a good time to invest, with some investors expecting a return to double digits.
$JAGX is experiencing a strong breakout, with many expecting big profits, and some even predicting a return to under $1 as a matter of when, not if.

Bearish· Sep 29

The company has a history of diluting its existing shareholder base, with a 165% increase in shares outstanding in a single week, contributing to a significant decline in stock price.
The company's products have consistently underperformed compared to current market drugs, and its business model has been criticized for being unsustainable and prone to repeated crashes.
The company's leadership, including the CEO, do not own a single share of the stock, raising concerns about their commitment to the company's success and potential conflicts of interest.

Generated by AI

Topics

Of the messages about JAGX that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	100%	5.15%	8.12%	20.93%
Technical Analysis	0%	16%	18.02%	15.02%
Analysts	0%	39.69%	37.23%	30.63%
Earnings	0%	0%	0%	1.63%
Macro	0%	39.06%	36.55%	31.72%
Controversies	0%	0.09%	0.08%	0.07%

Analysts· Jul 7

Cantor Fitzgerald analyst Louise Chen initiated coverage on Jaguar Health (JAGX) with an Overweight rating and a price target of $5.00.
Chen notes that the potential of Jaguar Health's antidiarrheal medication Mytesi (crofelemer) is underappreciated and expects upwards earnings estimate revisions to move the shares higher.
Mytesi sales rose to $1.2M in Q1 2021, indicating a 33.3% YoY growth, and Chen believes the company's pipeline in a product provides potential benefits in multiple gastrointestinal disorders.

Announcements· Jan 16

Jaguar Health, Inc. ($JAGX) has signed a $38M licensing deal with Future Pak for its Crofelemer products, providing a significant non-dilutive funding boost.
The deal includes an $18M upfront payment, with potential for up to $17M in milestone payments, and allows Jaguar Health to focus on rare diseases while retaining manufacturing.
Jaguar Health's stock price has surged following the announcement, with a 28.9% premarket increase, driven by the potential for growth in the HIV medication market.

Technical Analysis· Sep 25

$JAGX is showing signs of a reversal, with RSI oversold and a potential imminent break.
The stock has broken above the critical downtrend line and has a clear path to run ahead.
A cup and handle pattern is forming, indicating a bullish trend, with support zones at $8.7 and $9.69.

Generated by AI

Community

Of the messages about JAGX, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	32.89%	23.99%	24.5%	33.37%
Newcomers	67.11%	76.01%	75.5%	66.63%

Regulars· Sep 29

The preliminary results of an open-label study in adult short bowel syndrome patients with intestinal failure, using Jaguar Health's Crofelemer, have been accepted for presentation at the American College of Gastroenterology meeting, potentially providing a positive catalyst for the stock.
The founder and Managing Partner of Chicago Venture Partners, John M. Fife, has a significant stake in Jaguar Health, and his role has not been disclosed, which may be a concern for investors.
The stock price has been volatile, with some users anticipating a potential breakout, while others expect a further decline, with some users joking about the stock's prospects and the behavior of its investors.

Newcomers· Sep 29

A newcomer is speculating that $JAGX will surge 500-600% due to a potential massive short squeeze.
The company has announced that an abstract on a preliminary adult short bowel syndrome study results was accepted for presentation at ACG 2026, which may be a catalyst for the stock.
The company has recently diluted its existing shareholder base by approximately 165% in a single 48-hour window, which has led to a collapse in the stock price under heavy downward volume.

Generated by AI

Jaguar Health is surging on a float so thin that a handful of trades can swing the price wildly, while a rare pediatric disease program edges closer to a pivotal regulatory filing that could either validate the rally or expose how fragile it really is.

4d agoYahoo Finance

Jaguar Health Stock Surges Friday: What's Happening? - Jaguar Health (NASDAQ:JAGX)

Jaguar Health is surging Friday after announcing debt-for-equity exchanges that cut debt by over $6.7 million and retired a promissory note.

4d agoBenzinga

Jaguar Health Stock Slides Thursday: What's Happening? - Jaguar Health (NASDAQ:JAGX)

Jaguar Health shares are sliding Thursday as equity dilution concerns weigh on the company following a debt-for-equity exchange.

5d agoBenzinga

Viking Therapeutics Sinks 15% After Pricing Upsized $500M Offering; Jaguar Health Tumbles 25%

Two biotech stocks are getting crushed while the sector benchmark climbs, and the reasons behind each selloff could not be more different. Understanding what separates a deliberate corporate move from pure micro-cap chaos is the key to reading both situations correctly.

5d agoYahoo Finance

12 Health Care Stocks Moving In Wednesday's Intraday Session - Artelo Biosciences (NASDAQ:ARTL), Vistagen

Gainers Artelo Biosciences (NASDAQ:ARTL) shares rose 216.1% to $13.12 during Wednesday's regular session. The market value of their outstanding shares is at $2.2 million. Vistagen Therapeutics (NASDAQ:VTGN) shares

6d agoBenzinga

Also Discussed

Investors talking about JAGX also mention

#	Name	Attention
1	AVGR - Avinger, Inc.	——
2	NVCN - Neovasc Inc.	——
3	InspireMD, Inc.NSPR	0%new
4	Bionano Genomics Inc.BNGO	0%0
5	Check-Cap Ltd.CHEK	0%new
6	Top Ships Inc.TOPS	0%+0
7	My Size, Inc.MYSZ	0%new
8	OBLN - Obalon Therapeutics, Inc.	——
9	Lm Funding America Inc.LMFA	0%new
10	Oragenics Inc.OGEN	0%0

Jaguar Health, Inc.

Healthcare
Biotechnology

Jaguar Health, Inc. is a commercial-stage pharmaceuticals company focused on developing and commercializing plant-based gastrointestinal products for humans and animals. Its current business is organized around two segments, Human Health and Animal Health, covering prescription and non-prescription products for conditions such as chronic diarrhea, bowel urgency, and related gastrointestinal distress. The company’s human portfolio includes therapies for HIV-related diarrhea and other gastrointestinal indications, while its animal health activities target companion and production animals with digestive health needs. Jaguar Health also works through its subsidiaries to support proprietary products derived from sustainably sourced botanical ingredients. Headquartered in San Francisco, California, Jaguar Health plays a specialized role in the pharmaceutical market by addressing gastrointestinal disorders across both human and veterinary care.

Website

Location

200 Pine Street

San Francisco, CA, 94104

United States

Social

What share of all stock conversation is about JAGX?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0.02% -0.02	0.08% +0.04	0.02% +0.02	0% 0

Sep 29

Jaguar Health, Inc. has had a preliminary open-label study in adult short bowel syndrome patients with intestinal failure accepted for presentation at the annual American College of Gastroenterology meeting.
The study results involve the use of crofelemer, a product Jaguar Health, Inc. is developing, and the meeting is scheduled for October 9-14, 2026.
Some analysts predict a massive short squeeze to $50 for Jaguar Health, Inc.'s stock, with one post stating that the stock is "going to be big" and another predicting a price increase of $0.50+.

Generated by AI

Sentiment

Of the messages about JAGX that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	81.94% +17.77	72.05% -0.12	71.71% -11.15	65.56% +4.82
Bearish	18.06% -17.77	27.95% +0.12	28.29% +11.15	34.44% -4.82

Bullish· Sep 29

$JAGX is surging 500-600% and has a massive short squeeze coming soon, potentially reaching $50.
The company has released fantastic news, making it a good time to invest, with some investors expecting a return to double digits.
$JAGX is experiencing a strong breakout, with many expecting big profits, and some even predicting a return to under $1 as a matter of when, not if.

Bearish· Sep 29

The company has a history of diluting its existing shareholder base, with a 165% increase in shares outstanding in a single week, contributing to a significant decline in stock price.
The company's products have consistently underperformed compared to current market drugs, and its business model has been criticized for being unsustainable and prone to repeated crashes.
The company's leadership, including the CEO, do not own a single share of the stock, raising concerns about their commitment to the company's success and potential conflicts of interest.

Generated by AI

Topics

Of the messages about JAGX that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	100%	5.15%	8.12%	20.93%
Technical Analysis	0%	16%	18.02%	15.02%
Analysts	0%	39.69%	37.23%	30.63%
Earnings	0%	0%	0%	1.63%
Macro	0%	39.06%	36.55%	31.72%
Controversies	0%	0.09%	0.08%	0.07%

Analysts· Jul 7

Cantor Fitzgerald analyst Louise Chen initiated coverage on Jaguar Health (JAGX) with an Overweight rating and a price target of $5.00.
Chen notes that the potential of Jaguar Health's antidiarrheal medication Mytesi (crofelemer) is underappreciated and expects upwards earnings estimate revisions to move the shares higher.
Mytesi sales rose to $1.2M in Q1 2021, indicating a 33.3% YoY growth, and Chen believes the company's pipeline in a product provides potential benefits in multiple gastrointestinal disorders.

Announcements· Jan 16

Jaguar Health, Inc. ($JAGX) has signed a $38M licensing deal with Future Pak for its Crofelemer products, providing a significant non-dilutive funding boost.
The deal includes an $18M upfront payment, with potential for up to $17M in milestone payments, and allows Jaguar Health to focus on rare diseases while retaining manufacturing.
Jaguar Health's stock price has surged following the announcement, with a 28.9% premarket increase, driven by the potential for growth in the HIV medication market.

Technical Analysis· Sep 25

$JAGX is showing signs of a reversal, with RSI oversold and a potential imminent break.
The stock has broken above the critical downtrend line and has a clear path to run ahead.
A cup and handle pattern is forming, indicating a bullish trend, with support zones at $8.7 and $9.69.

Generated by AI

Community

Of the messages about JAGX, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	32.89%	23.99%	24.5%	33.37%
Newcomers	67.11%	76.01%	75.5%	66.63%

Regulars· Sep 29

The preliminary results of an open-label study in adult short bowel syndrome patients with intestinal failure, using Jaguar Health's Crofelemer, have been accepted for presentation at the American College of Gastroenterology meeting, potentially providing a positive catalyst for the stock.
The founder and Managing Partner of Chicago Venture Partners, John M. Fife, has a significant stake in Jaguar Health, and his role has not been disclosed, which may be a concern for investors.
The stock price has been volatile, with some users anticipating a potential breakout, while others expect a further decline, with some users joking about the stock's prospects and the behavior of its investors.

Newcomers· Sep 29

A newcomer is speculating that $JAGX will surge 500-600% due to a potential massive short squeeze.
The company has announced that an abstract on a preliminary adult short bowel syndrome study results was accepted for presentation at ACG 2026, which may be a catalyst for the stock.
The company has recently diluted its existing shareholder base by approximately 165% in a single 48-hour window, which has led to a collapse in the stock price under heavy downward volume.

Generated by AI

Jaguar Health

Social

Sep 29

Bullish· Sep 29

Bearish· Sep 29

Analysts· Jul 7

Announcements· Jan 16

Technical Analysis· Sep 25

Regulars· Sep 29

Newcomers· Sep 29

Preliminary Results of Open-Label Study in Adult Short Bowel Syndrome Patients with Intestinal Failure (SBS-IF) with Jaguar Health's Crofelemer Accepted for Presentation at Annual American College of Gastroenterology Meeting

Jaguar Health Soars 32% as Rare-Disease Pipeline News Meets Thin Post-Split Float

Jaguar Health Stock Surges Friday: What's Happening? - Jaguar Health (NASDAQ:JAGX)

Jaguar Health Stock Slides Thursday: What's Happening? - Jaguar Health (NASDAQ:JAGX)

Viking Therapeutics Sinks 15% After Pricing Upsized $500M Offering; Jaguar Health Tumbles 25%

12 Health Care Stocks Moving In Wednesday's Intraday Session - Artelo Biosciences (NASDAQ:ARTL), Vistagen

Also Discussed

Jaguar Health, Inc.

Company Information

Location

Preliminary Results of Open-Label Study in Adult Short Bowel Syndrome Patients with Intestinal Failure (SBS-IF) with Jaguar Health's Crofelemer Accepted for Presentation at Annual American College of Gastroenterology Meeting

Jaguar Health Soars 32% as Rare-Disease Pipeline News Meets Thin Post-Split Float

Jaguar Health Stock Surges Friday: What's Happening? - Jaguar Health (NASDAQ:JAGX)

Jaguar Health Stock Slides Thursday: What's Happening? - Jaguar Health (NASDAQ:JAGX)

Viking Therapeutics Sinks 15% After Pricing Upsized $500M Offering; Jaguar Health Tumbles 25%

12 Health Care Stocks Moving In Wednesday's Intraday Session - Artelo Biosciences (NASDAQ:ARTL), Vistagen

Also Discussed

Social

Sep 29

Bullish· Sep 29

Bearish· Sep 29

Analysts· Jul 7

Announcements· Jan 16

Technical Analysis· Sep 25

Regulars· Sep 29

Newcomers· Sep 29